Brentuximab vedotin for frontline Hodgkin lymphoma: How much will a successful trial cost patients and payers?

Satish Shanbhag; Vinay Prasad

doi:10.1016/j.ejca.2018.09.021

Brentuximab vedotin for frontline Hodgkin lymphoma: How much will a successful trial cost patients and payers?

Satish Shanbhag, Vinay Prasad

Knight Cancer Institute

Research output: Contribution to journal › Letter › peer-review

5 Scopus citations

Original language	English (US)
Pages (from-to)	252-253
Number of pages	2
Journal	European Journal of Cancer
Volume	104
DOIs	https://doi.org/10.1016/j.ejca.2018.09.021
State	Published - Nov 2018

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1016/j.ejca.2018.09.021

Cite this

@article{4a0d457fa7d64c9e81061daf16594027,

title = "Brentuximab vedotin for frontline Hodgkin lymphoma: How much will a successful trial cost patients and payers?",

author = "Satish Shanbhag and Vinay Prasad",

note = "Funding Information: Dr. Prasad reports receiving royalties from his book Ending Medical Reversal, that his work is funded by the Laura and John Arnold Foundation, that he has received honoraria for Grand Rounds/lectures from several universities, medical centers, nonprofit groups, professional societies, and is a writer for Medscape. Copyright: Copyright 2019 Elsevier B.V., All rights reserved.",

year = "2018",

month = nov,

doi = "10.1016/j.ejca.2018.09.021",

language = "English (US)",

volume = "104",

pages = "252--253",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Brentuximab vedotin for frontline Hodgkin lymphoma

T2 - How much will a successful trial cost patients and payers?

AU - Shanbhag, Satish

AU - Prasad, Vinay

N1 - Funding Information: Dr. Prasad reports receiving royalties from his book Ending Medical Reversal, that his work is funded by the Laura and John Arnold Foundation, that he has received honoraria for Grand Rounds/lectures from several universities, medical centers, nonprofit groups, professional societies, and is a writer for Medscape. Copyright: Copyright 2019 Elsevier B.V., All rights reserved.

PY - 2018/11

Y1 - 2018/11

UR - http://www.scopus.com/inward/record.url?scp=85056584873&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056584873&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2018.09.021

DO - 10.1016/j.ejca.2018.09.021

M3 - Letter

C2 - 30342911

AN - SCOPUS:85056584873

SN - 0959-8049

VL - 104

SP - 252

EP - 253

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -

Brentuximab vedotin for frontline Hodgkin lymphoma: How much will a successful trial cost patients and payers?

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this